Novartis Gains Phase II COPD Agent In Deal Worth Up To $375 Mil.
This article was originally published in The Pink Sheet Daily
Executive Summary
Novartis will assume Phase III testing of anti-muscarinic from U.K. companies Vectura and Arakis. AD 237 will be evaluated in head-to-head comparison against Pfizer/Boehringer Ingelheim's Spiriva; companies believe AD 237 has a better safety profile than tiotropium.You may also be interested in...
Vectura, Unilever Establish Specialty Pharmaceutical Company
Oncology Pilot To Highlight Disagreements Between US FDA And Sponsor For Advisory Committees
'Point/Counterpoint' program grew out of Assessment Aid initiative in the Oncology Center of Excellence and will be unveiled at an upcoming ODAC meeting.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: